Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Posted by rob on December 31, 2010 under Uncategorized | 
Comments are off for this article
Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):452-7
Authors: Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L
Although initially responsive to therapy, indolent non-Hodgkin lymphomas (NHLs) are generally incurable. Therefore, active and tolerable treatments for patients with relapsed or refractory disease are needed. Bendamustine, a mechlorethamine alkylator with novel mechanisms of action, is approved in the United States for rituximab-refractory indolent B-cell NHL.
PMID: 21189660 [PubMed - in process]